References
- Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992; 14: 131–53
- Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995; 168(Suppl 29): 7–12
- Altwein JE. Individualization of treatment in benign prostatic hyperplasia. Eur Urol 1996; 29(Suppl 1): 2–6
- Tsang KK, Garraway WM. Prostatism and the burden of benign prostatic hyperplasia on elderly men. Age Ageing 1994; 23(5): 360–4
- Cadieux RJ. Geriatric psychopharmacology: a primary care challenge. Postgrad Med 1993; 93(4): 281–301
- McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Quick reference guide for clinicians. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, Dept of Health and Human Services, 1994 Feb; AHCPR publication No. 94–0583
- Cockett AT, Aso Y, Denis L, et al. Recommendations of the International Consensus Committee. In: Cockett AT, Khoury S, Aso Y, et al. Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey: Scientific Communication International Ltd, 1996: 625–40
- Measurement Committee of the American Urological Association. American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148(5): 1549–57
- Mebust WK, Holtgrewe HL, Cockett AT, et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141(2): 243–7
- Wyatt MG, Stower MJ, Smith PJ, et al. Prostatectomy in the over 80-year-old. Br J Urol 1989; 64(4): 417–9
- Landsberg L. Unique problems in the treatment of the older hypertensive male. Introduction: increased sympathetic nervous system activity in the elderly. Br J Clin Pract 1994; 74(Symp Suppl): 1–3
- Pool JL. Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract 1994; 74(Symp Suppl): 13–7
- Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993; 3(3): 258–77
- Kaplan SA. Doxazosin in the older male: efficacy in treating benign prostatic hyperplasia. Eur Urol 1996; 29(Suppl 1): 17–23
- Vincent J, Meredith PA, Elliott HL, et al. The pharmacokinetics of doxazosin in elderly normotensives. Br J Clin Pharmacol 1986; 21(5): 521–4
- Kaplan SA, Soldo KA, Olsson CA. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. Eur Urol 1995; 28(3): 223–8
- Langdon CG, Packard RS. Doxazosin in hypertension: results of a general practice study in 4809 patients. Br J Clin Pract 1994; 48(6): 293–8
- Jardin A, Kirby R, Christensen MM, et al. Doxazosin is equally well tolerated by older and younger normotensive men. J Urol 1995; 153(Suppl): 273A, abstr 179
- The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22(4): 291–9
- McConnell J, Akakura K, Akaza H, et al. Hormonal treatment of benign prostatic hyperplasia. In: Cockett et al, Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH), 7 pp 497–526
- Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335(8): 533–9